MEI Pharma, Inc.

Please note: The information displayed on this page might be outdated.
MEI Pharma, Inc.: Four clinical-stage oncology candidates, multiple 2021 milestones. Upcoming events include enrollment completion in the TIDAL study intended to support accelerated approval of lead candidate zandelisib (PI3K delta inhibitor) in r/r follicular lymphoma. Enrollment guided to complete in the first quarter of 2021; primary efficacy endpoint is 6 month ORR. Broadening zandelisib development activity includes addition of marginal zone lymphoma arm to TIDAL to support expansion of an accelerated approval strategy if successful, the initiation of a Phase 3 study in second line follicular and marginal zone lymphomas in mid-2021, and plans to support select investigator-initiated trials, initially in first-line DLBCL. Milestones also include Initial phase 1b data from study evaluating zandelisib with Brukinsa™ in collaboration with BeiGene. Anticipated updates in other programs include: voruciclib Initial data from the Phase 1 monotherapy and +BCL2i Phase 1b; pracinostat phase 2 MDS update from partner Helsinn; and ME-344 plan to leverage clinically demonstrated anti-tumor activity in combination with anti-VEGF.
Based in...
US - Pacific, USA
Clinical Stage
Phase III, Phase l or ll, Pivotal
Disease Space
DLBCL, Hematology, Marginal Zone (mzl), Oncology
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
B Cell, pi3k, Small Molecule, Targeted Therapy
3611 Valley Centre Drive
Suite 500
San Diego, CA 92130
United States

Company Participants at Solebury Trout Virtual Management Access Event 2021

Daniel Gold
MEI Pharma, Inc., CEO & President
Dr. Gold was appointed President, Chief Executive Officer and a director in April 2010. He joined the Company with approximately 25 years of drug discovery and development experience, most recently as President and Chief Executive Officer of Prospect Therapeutics, a mid-stage oncology company. Prior to his tenure at Prospect, Dr. Gold was founder and Chief Scientific Officer of Favrille, where he was an integral member of a team that raised more than $200 million to advance the company's lead oncology candidate through a pivotal Phase III clinical trial. He currently serves on the Board of Trustees of the Hope Funds for Cancer Research. Dr. Gold's academic qualifications include Postdoctoral Fellowships at the Dana-Farber Cancer Institute, at the Harvard School of Medicine and the Massachusetts Institute of Technology, Center for Cancer Research. He holds a Ph.D. in Pathology/Immunology from Tufts University, Boston and a bachelor's degree in Biology from the University of California Los Angeles.

Top 10 Holders of MEI Pharma, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Bioimpact Capital LLC 11.09 12,494,118 31.11 13F 9/30/21
First Light Asset Management LLC 7.67 8,637,475 21.51 13F 9/30/21
NEA Management Co. 7.57 8,533,072 21.25 13F 9/30/21
The Vanguard Group, Inc. 7.54 8,498,565 21.16 Funds 11/30/21
Wasatch Advisors, Inc. 5.63 6,339,734 15.79 13F 9/30/21
Vanguard Group, Inc. (Subfiler) 4.50 5,070,047 12.62 13F 9/30/21
BlackRock Fund Advisors 3.24 3,652,441 9.09 13F 9/30/21
BVF, Inc. 3.13 3,532,057 8.79 13F 9/30/21
Boxer Capital LLC 2.59 2,913,091 7.25 13F 9/30/21
BlackRock Institutional Trust Co. NA 2.14 2,415,364 6.01 13F 9/30/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.